This trial is testing a new anti-cancer drug (venetoclax) to see if it can help treat patients with chronic lymphocytic leukemia who have not received previous treatment. The drug is being added to the usual treatment of ibrutinib and obinutuzumab. The trial will also investigate whether patients who receive all three treatments and have no detectable chronic lymphocytic leukemia after one year of treatment, can stop taking ibrutinib.
1 Primary · 3 Secondary · Reporting Duration: Up to 10 years
454 Total Participants · 2 Treatment Groups
Primary Treatment: Observation · No Placebo Group · Phase 3
Age 65+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: